Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates

While Biogen’s Q3 revenue dipped by 10% versus the prior year, the company focused its earnings call on two bright prospects — recently unveiled positive results for lecanemab, its anti-amyloid Alzheimer’s follow-up to Aduhelm, and its potential ALS drug tofersen.